CR20250329A - Compuestos tricíclicos para el tratamiento del cáncer - Google Patents
Compuestos tricíclicos para el tratamiento del cáncerInfo
- Publication number
- CR20250329A CR20250329A CR20250329A CR20250329A CR20250329A CR 20250329 A CR20250329 A CR 20250329A CR 20250329 A CR20250329 A CR 20250329A CR 20250329 A CR20250329 A CR 20250329A CR 20250329 A CR20250329 A CR 20250329A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer
- treatment
- tricyclic compounds
- sup
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (Ib), (Ib), en donde R1 a R3 , M y L son como se describen en la presente, y su sal aceptable desde el punto de vista farmacéutico, enantiómeros o diastereómeros de estos, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023075911 | 2023-02-14 | ||
| CN2023115515 | 2023-08-29 | ||
| CN2024074420 | 2024-01-29 | ||
| PCT/CN2024/076886 WO2024169914A1 (en) | 2023-02-14 | 2024-02-08 | Tricyclic compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250329A true CR20250329A (es) | 2025-09-12 |
Family
ID=90363897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250329A CR20250329A (es) | 2023-02-14 | 2024-02-08 | Compuestos tricíclicos para el tratamiento del cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12247036B2 (es) |
| EP (1) | EP4469164A1 (es) |
| JP (1) | JP2026506637A (es) |
| KR (1) | KR20250129811A (es) |
| CN (1) | CN120813588A (es) |
| AU (1) | AU2024220916A1 (es) |
| CL (1) | CL2025002160A1 (es) |
| CO (1) | CO2025010435A2 (es) |
| CR (1) | CR20250329A (es) |
| IL (1) | IL322109A (es) |
| MX (1) | MX2025009239A (es) |
| PE (1) | PE20252395A1 (es) |
| WO (1) | WO2024169914A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025201453A1 (en) * | 2024-03-28 | 2025-10-02 | Beigene (Suzhou) Co., Ltd. | Macrocyclic compounds as ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025252864A1 (en) * | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Macrocyclic compounds for the treatment of cancer |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026022119A1 (en) * | 2024-07-24 | 2026-01-29 | F. Hoffmann-La Roche Ag | Ras inhibitors in combination therapy for use in treating cancers |
| WO2026027450A1 (en) * | 2024-07-29 | 2026-02-05 | F. Hoffmann-La Roche Ag | Solid forms of ras inhibitor |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026061441A1 (en) * | 2024-09-19 | 2026-03-26 | Beone Pharmaceutical (Suzhou) Co., Ltd. | Macrocyclic compounds as ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026082180A1 (zh) * | 2024-10-18 | 2026-04-23 | 合肥盛浦医药科技有限公司 | 一种大环化合物、其中间体、其制备方法及其应用 |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20260115199A1 (en) | 2024-10-31 | 2026-04-30 | Hoffmann-La Roche Inc. | Tricyclic compounds for the treatment of cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019009903A2 (pt) | 2016-11-18 | 2019-08-13 | Neurovive Pharmaceutical Ab | análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b |
| IL317393A (en) | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
| MX2022005359A (es) * | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CR20230500A (es) | 2021-04-02 | 2024-02-13 | Massachusetts Gen Hospital | Métodos para inhibir ras |
| CN117597354A (zh) | 2021-04-02 | 2024-02-23 | 综合医院公司 | 抑制ras的方法 |
| CN117979966A (zh) | 2021-04-09 | 2024-05-03 | 锐新医药公司 | 使用sos1抑制剂和ras抑制剂治疗癌症 |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| WO2022251292A1 (en) | 2021-05-25 | 2022-12-01 | Revolution Medicines, Inc. | Methods for inhibiting ras |
| WO2023015559A1 (en) | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (es) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento de cáncer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| US20250066386A1 (en) | 2021-11-09 | 2025-02-27 | Biomea Fusion, Inc. | Inhibitors of kras |
| EP4463231A1 (en) | 2022-01-10 | 2024-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN119156393A (zh) | 2022-04-25 | 2024-12-17 | 翰森生物有限责任公司 | 环状化合物及其制备方法和医药用途 |
| WO2023232776A1 (en) | 2022-06-01 | 2023-12-07 | F. Hoffmann-La Roche Ag | Haloindole macrocyclic compounds for the treatment of cancer |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AR129819A1 (es) | 2022-07-04 | 2024-10-02 | Hoffmann La Roche | Compuestos de haloalquinilo para el tratamiento de cáncer |
| EP4551295A1 (en) | 2022-07-08 | 2025-05-14 | F. Hoffmann-La Roche AG | Macrocycle compounds useful as kras inhibitors |
| AR129934A1 (es) | 2022-07-20 | 2024-10-16 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento de cáncer |
| JP2025528836A (ja) | 2022-08-17 | 2025-09-02 | ツリーライン バイオサイエンシズ インコーポレイテッド | ピリドピリミジンＫＲａｓ阻害剤 |
| CN117720555B (zh) | 2022-09-19 | 2026-05-05 | 杭州阿诺生物医药科技有限公司 | 一种制备kras抑制剂化合物的中间体及其合成方法 |
| CN117903169A (zh) | 2022-09-19 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| CN120693161A (zh) | 2022-10-12 | 2025-09-23 | 锐新医药公司 | 用于治疗癌症的包含第一ras抑制剂、第二ras抑制剂以及shp2抑制剂的组合物 |
| JP2025539080A (ja) | 2022-11-14 | 2025-12-03 | アムジエン・インコーポレーテツド | 大環状ｋｒａｓ阻害剤及び使用方法 |
| LU505465B1 (en) | 2022-11-16 | 2024-05-14 | Adlai Nortye Biopharma Co Ltd | A pan-KRAS inhibitor compound |
| CN118047799A (zh) | 2022-11-16 | 2024-05-17 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| LU505464B1 (en) | 2022-11-18 | 2024-05-13 | Adlai Nortye Biopharma Co Ltd | A pan-KRAS inhibitor compound |
| CN117534684A (zh) | 2022-11-29 | 2024-02-09 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| EP4649081A1 (en) | 2023-01-13 | 2025-11-19 | F. Hoffmann-La Roche AG | Sulfonylvinyl compounds for the treatment of cancer |
| CN120615093A (zh) | 2023-01-19 | 2025-09-09 | 劲方医药科技(上海)股份有限公司 | 大环化合物及其制法和用途 |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
-
2024
- 2024-02-08 PE PE2025001629A patent/PE20252395A1/es unknown
- 2024-02-08 KR KR1020257026943A patent/KR20250129811A/ko active Pending
- 2024-02-08 IL IL322109A patent/IL322109A/en unknown
- 2024-02-08 AU AU2024220916A patent/AU2024220916A1/en active Pending
- 2024-02-08 CN CN202480012060.7A patent/CN120813588A/zh active Pending
- 2024-02-08 WO PCT/CN2024/076886 patent/WO2024169914A1/en not_active Ceased
- 2024-02-08 CR CR20250329A patent/CR20250329A/es unknown
- 2024-02-08 JP JP2025546394A patent/JP2026506637A/ja active Pending
- 2024-02-08 EP EP24710602.4A patent/EP4469164A1/en active Pending
- 2024-08-22 US US18/812,060 patent/US12247036B2/en active Active
-
2025
- 2025-02-04 US US19/045,449 patent/US20250376482A1/en active Pending
- 2025-07-22 CL CL2025002160A patent/CL2025002160A1/es unknown
- 2025-07-30 CO CONC2025/0010435A patent/CO2025010435A2/es unknown
- 2025-08-07 MX MX2025009239A patent/MX2025009239A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20252395A1 (es) | 2025-10-10 |
| KR20250129811A (ko) | 2025-08-29 |
| US20250376482A1 (en) | 2025-12-11 |
| CL2025002160A1 (es) | 2025-08-22 |
| AU2024220916A1 (en) | 2025-05-29 |
| CN120813588A (zh) | 2025-10-17 |
| US12247036B2 (en) | 2025-03-11 |
| IL322109A (en) | 2025-09-01 |
| US20240417410A1 (en) | 2024-12-19 |
| WO2024169914A1 (en) | 2024-08-22 |
| EP4469164A1 (en) | 2024-12-04 |
| MX2025009239A (es) | 2025-09-02 |
| CO2025010435A2 (es) | 2025-08-19 |
| JP2026506637A (ja) | 2026-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| CR20240312A (es) | Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias | |
| CR20230566A (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2025009239A (es) | Compuestos triciclicos para el tratamiento de cancer | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| MX2023012907A (es) | Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3). | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
| WO2020210320A8 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| MX2021012223A (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. | |
| MX2023009379A (es) | Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer. | |
| WO2024006726A3 (en) | Compounds as inhibitors of axl | |
| MX2023015139A (es) | Inhibidores de mutacion de her2. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025004959A (es) | Derivados de triazinona como inhibidores de inflamasoma de proteina 3 que contiene dominios de pirina (nlrp3) | |
| CR20220478A (es) | Derivados de benzodiazepinas como pam de gaba a gamma 1 | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
| WO2025188946A8 (en) | Wee1 inhibitors and methods for treating cancer | |
| MX2024003645A (es) | Derivados de piridinilacetamida como activadores de canales de sodio. | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2025008428A (es) | Derivados de piperidina como inhibidores de mettl3 | |
| MX2025002166A (es) | Compuestos y metodos para modular her2 | |
| MX2024003647A (es) | Derivados de piridina y su uso como activadores del canal de sodio. | |
| MX2023007550A (es) | Compuestos de aminobencil heteroarilo sustituidos como inhibidores de receptor de factor de crecimiento epidermico (egfr) y/o fosfoinositol 3-cinasa (pi3k). |